Clinical Study
An Open-Label Trial of Memantine for Cognitive Impairment in Patients with Posttraumatic Stress Disorder
Table 3
Estimated means and standard errors for secondary outcome scores at each visit (from ME model).
| ā | Week | Mean | SE | value |
| CAPS-B | Baseline | 20.65 | 1.73 | 0.52 | End of week 8 | 19.10 | 1.62 | End of week 16 | 19.17 | 1.60 |
| CAPS-C | Baseline | 33.31 | 1.54 | 0.0055 | End of week 8 | 27.98 | 2.08 | End of week 16 | 26.92 | 1.97 |
| CAPS-D | Baseline | 24.88 | 0.97 | 0.023 | End of week 8 | 21.88 | 1.58 | End of week 16 | 20.75 | 1.44 |
| CAPS total score | Baseline | 78.85 | 3.79 | 0.027 | End of week 8 | 68.92 | 4.72 | End of week 16 | 66.80 | 4.45 |
| HAM-A | Baseline | 25.04 | 1.71 | 0.056 | End of week 8 | 20.76 | 1.99 | End of week 16 | 20.18 | 1.74 |
| HAM-D | Baseline | 19.96 | 1.17 | 0.013 | End of week 8 | 14.57 | 1.36 | End of week 16 | 15.53 | 1.54 |
| Q-LES-Q | Baseline | 40.27 | 1.79 | 0.0076 | End of week 8 | 47.07 | 2.25 | End of week 16 | 46.81 | 2.21 |
| SDS | Baseline | 7.02 | 0.31 | 0.020 | End of week 8 | 6.20 | 0.66 | End of week 16 | 5.73 | 0.50 |
|
|